You are here: Industry Insights > BeiGene

News List

MEI Pharma, BeiGene to co-develop cancer drug biospectrum
October 15, 2018
Under the terms of the clinical collaboration agreement, MEI will amend its ongoing Phase 1b trial to include evaluation of ME-401 in combination with zanubrutinib in patients with B-cell malignancies
MEI Pharma, BeiGene Collaborate on ME-401, Zanubrutinib Combination americanpharmaceuticalreview
October 12, 2018
MEI Pharma and BeiGene announced a clinical collaboration to evaluate the safety and efficacy of MEI's ME-401, an investigational PI3K delta inhibitor, in combination with BeiGene's zanubrutinib, an investigational BTK inhibitor, for the treatment of pati
BeiGene picks GE’s facility to boost cancer drugs production capacity biospectrumasia
September 19, 2018
BeiGene to build late-stage clinical and commercial production capacity for cancer monoclonal antibodies with GE Healthcare’s KUBio, the prefabricated biopharma facility based on single-use technologies
BeiGene and SpringWorks Therapeutics Enter into Global Clinical Collaboration to Evaluate Targeted Combination Therapy in Advanced Solid Tumors pharmafocusasia
September 10, 2018
BeiGene, Ltd., a commercial-stage biopharmaceutical company focused on developing and commercializing innovative molecularly-targeted and immuno-oncology drugs for the treatment of cancer, and SpringWorks Therapeutics, a clinical-stage rare disease and on
FiercePharmaAsia—Aurobindo’s $1B Sandoz buy; ex-GSK scientist guilty plea; Chi-Med’s Elunate win fiercepharma
September 10, 2018
Aurobindo, Novartis' Sandoz, a former GSK scientist and Chi-Med made our news this week.
BeiGene Announces Acceptance of its First NDA for Zanubrutinib biospectrumasia
August 30, 2018
Zanubrutinib is being studied in several clinical trials as part of a broad development program and was recently granted Fast Track Designation by the US FDA
BeiGene appoints J. Samuel Su to its Board of Directors biospectrumasia
April 10, 2018
BeiGene is advancing a pipeline consisting of novel oral small molecules and monoclonal antibodies for cancer
BeiGene Initiates Global Phase III Trial of Anti-PD-1 Antibody Tislelizumab in Patients With Hepatoc biospace
January 03, 2018
BeiGene today announced that the first patient in the world in December 2017 was tislelizumab, an investigational anti-PD-1 antibody, for the phase 3 clinical trial of patients with previously untreated advanced hepatocellular carcinoma
FiercePharmaAsia—Sun’s quarterly loss, BeiGene’s $175M public offering, Biocon plant’s extensive pro fiercepharma
August 14, 2017
Sun Pharma took a hit with a 9.51 billion rupees antitrust settlement over Modafinil, a sleep disorder treatment.
BeiGene to develop $330 million biologics plant in China pharmafile
March 08, 2017
BeiGene, a Chinese biotech company, and Guangzhou GET Technology Development, an affiliate of Guangzhou Development District, will partner in the...

Previous page 1 2 3 4 Next page